The AMR Alliance
Pharmadanmark has focused on antimicrobial resistance (AMR) for many years. In 2024, we co-founded the Danish AMR Alliance together with the Novo Nordisk Foundation and Pfizer Denmark.
Antimicrobial resistance (AMR) is a serious threat to society.
Each year, AMR is responsible for approximately 35,000 deaths in Europe. According to the World Health Organization (WHO), projections estimate that up to 10 million people could die annually by 2050 if current trends continue.
This presents a critical challenge for patients, as effective antibiotics may no longer be available. It is also a growing concern for healthcare professionals – including many of our members – who work in hospitals or interact with patients in pharmacies.
Pharmadanmark has worked actively on AMR for several years.
In 2024, we joined forces with the Novo Nordisk Foundation and Pfizer Denmark to establish the Danish AMR Alliance.
Today, the alliance includes more than 45 organisations and serves as the secretariat for the advisory group supporting the national action plan on antimicrobial resistance in humans.
“Antibiotics were essential to my treatment”
It is crucial that we take action against the AMR threat. This was the key message from policymakers, experts, and patients at the AMR conference held in Aarhus and Copenhagen in November 2025.
World Congress in Copenhagen leads to new AMR declaration
AMR was the main focus at the FIP World Congress in Copenhagen. The day opened with a speech by Minister for the Interior and Health, Sophie Løhde, and concluded with a ceremony where 80 organisations signed a global declaration to combat AMR.
Antibiotic resistance threatens cancer treatment
Across Denmark, fundraising campaigns and awareness initiatives highlight cancer. However, one important – and often overlooked – aspect of the conversation is antimicrobial resistance and its impact on treatment outcomes.
Sign up today
Would you also like access to strong member benefits and a network that strengthens your career?
